Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERSONALIS, INC.

(PSNL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing

10/12/2021 | 09:10am EST

Mayo Clinic announced an agreement on that will allow it to offer clinical-grade comprehensive cancer genomic sequencing to cancer patients who choose to participate. Test results will be available to patients and their treating health care providers to guide therapeutic decisions, advance cancer research, and support the development of new diagnostic tests and therapies for cancer treatment. Mayo Clinic Cancer Center, Mayo Clinic's Department of Laboratory Medicine and Pathology, and Mayo Clinic'sCenter for Individualized Medicine are collaborating with Personalis Inc., a cancer genomics company whose clinical-grade, comprehensive cancer genomic test includes sequencing the entire coding genome through whole-exome and transcriptome sequencing. The test will provide a clinical report for each patient and comprehensive aggregated data that Mayo Clinic and Personalis will use to further develop this comprehensive diagnostic approach.


© S&P Capital IQ 2021
All news about PERSONALIS, INC.
11/18Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conferenc..
BU
11/12Personalis Named to Inc.'s 2021 Best-Led Companies List
BU
11/11Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th A..
BU
11/11Personalis to Present New Data at the Society for Immunotherapy of Cancer 36th Annual M..
CI
11/08Morgan Stanley Downgrades Personalis to Equalweight from Overweight, Adjusts Price Targ..
MT
11/04Personalis Q3 Net Loss Widens Despite Revenue Growth, Tightens Loss Guidance; Stock Ris..
MT
11/04PERSONALIS : Q3 Earnings Snapshot
AQ
11/04PERSONALIS, INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/04Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
11/04Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $22.3M, vs. Street Est of $22.2M
MT
More news
Analyst Recommendations on PERSONALIS, INC.
More recommendations
Financials (USD)
Sales 2021 85,1 M - -
Net income 2021 -67,3 M - -
Net cash 2021 287 M - -
P/E ratio 2021 -9,14x
Yield 2021 -
Capitalization 627 M 627 M -
EV / Sales 2021 3,99x
EV / Sales 2022 6,59x
Nbr of Employees 235
Free-Float 98,1%
Chart PERSONALIS, INC.
Duration : Period :
Personalis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERSONALIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 13,99 $
Average target price 32,00 $
Spread / Average Target 129%
EPS Revisions
Managers and Directors
John S. West President, Chief Executive Officer & Director
Aaron Tachibana Chief Financial Officer
Jonathan J. MacQuitty Chairman
Richard O. Chen Chief Scientific Officer
Xavier Paliard Vice President-Immunology, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PERSONALIS, INC.-61.79%627
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431